Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abiomed, Inc.
Journal of the American College of Cardiology Publishes PROTECT I Study Results for Abiomed Impella 2.5
March 26th, 2009
Results from the PROTECT I trial evaluating the feasibility and effectiveness of the Abiomed, Inc. (NASDAQ: ABMD) Impella 2.5 circulatory assist device in high-risk percutaneous coronary intervention (PCI) procedures have been published in the February issue of the Journal of the American College of Cardiology (JACC). The study, “A Prospective Feasibility Trial Investigating the Use of the Impella 2.5 System in Patients Undergoing High-Risk Percutaneous Coronary Intervention (The PROTECT I Trial)¹” concludes that “The Impella 2.5 system is safe, easy to use, and provides excellent hemodynamic support during high-risk PCI [percutaneous coronary intervention].” The...
Source: Women's Health Weekly (2009-03-26)
|
|
Advertisement |
|
|
|
